Beta-2 Polymorphisms and Beta Receptor Selectivity
We hypothesize that b2 adrenergic polymorphisms affect b-receptor selectivity in patients with heart failure treated with either a b1-selective or a b-nonselective agent. b-2 polymorphisms may contribute to differing responses to drug treatment with beta-blockers in heart failure. Characterizing these polymorphisms may help explain the variability in the degree of “selectivity” of action of...
Brief Summary
Official Title: “The Effects of ß2 Polymorphisms on Beta Selectivity After ß-Adrenergic Blockade in Patients With Heart Failure”
We hypothesize that b2 adrenergic polymorphisms affect b-receptor selectivity in patients with heart failure treated with either a b1-selective or a b-nonselective agent. b-2 polymorphisms may contribute to differing responses to drug treatment with beta-blockers in heart failure. Characterizing these polymorphisms may help explain the variability in the degree of “selectivity” of action of b-blockers at the b receptor, namely if their action is specific for the b-1 or b-2 receptor. Part A was conducted at the University of Utah, and all subjects completed study related activities. Part B (sub-study) consists of genotyping of blood samples collected in part A, which will be completed at the University of Wisconsin. Sub-study (samples and DNA isolation) or Part B entailed analyzing an extra 10 mL of blood that was taken for DNA isolation. Genotyping (i.e. determination of genetic makeup) of beta adrenergic polymorphisms utilized polymerase chain reaction followed by pyrosequencing.
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Intervention(s) in this Clinical Trial
- Drug: Terbutaline plus Metoprolol or carvedilol
Outcome Measures for this Clinical Trial
Primary Measures
- The effect of beta-2 polymorphisms on potassium changes in response to terbutaline infusions
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- systolic dysfunction with ejection fraction ≤40%
- symptomatic heart failure class 2-3
- >18 years of age
- optimal medical therapy of HF excluding the use of any beta-blockers within the previous 30 days of the study
Exclusion Criteria:
- active myocarditis
- hemodynamically significant valvular heart disease
- hypertrophic cardiomyopathy
- contra-indications to beta-blockers
- concomitant use of beta-agonists
- beta-antagonist or anti-arrhythmics
- unstable angina
- myocardial infarction or bypass surgery within 3 months
- significant renal insufficiency [creatinine >2.5 mg/dL], liver disease, or anemia
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: University of Wisconsin, Madison Other
Overall Clinical Trial Officials and Contacts
orly vardeny Principal Investigator University of Wisconsin, Madison
Additional Information
Information obtained from ClinicalTrials.gov on February 09, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00214318
Study ID Number: M-2005-0006
ClinicalTrials.gov Identifier: NCT00214318
Health Authority: United States: Institutional Review Board
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00214318
